Aliases & Classifications for Paraplegia

MalaCards integrated aliases for Paraplegia:

Name: Paraplegia 12 72 49 41 14 69
Severe or Complete Loss of Motor Function in the Lower Extremities and Lower Portions of the Trunk 49
Paraplegia, Lower 12

Classifications:



External Ids:

Disease Ontology 12 DOID:607
ICD10 32 G82.2 G82.20
ICD9CM 34 344.1
MeSH 41 D010264
NCIt 46 C50687
SNOMED-CT 64 155031004 60389000
UMLS 69 C0030486

Summaries for Paraplegia

MalaCards based summary : Paraplegia, also known as severe or complete loss of motor function in the lower extremities and lower portions of the trunk, is related to spastic paraplegia 11, autosomal recessive and spastic paraplegia 5a, autosomal recessive, and has symptoms including paraplegia, flaccid, monoplegia of lower limb affecting unspecified side and paraplegia, spinal. An important gene associated with Paraplegia is SPG7 (SPG7, Paraplegin Matrix AAA Peptidase Subunit), and among its related pathways/superpathways is Endocytosis. The drugs Acetazolamide and diuretics have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and bone, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 72 Paraplegia is an impairment in motor or sensory function of the lower extremities. The word comes from... more...

Related Diseases for Paraplegia

Diseases related to Paraplegia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 491)
# Related Disease Score Top Affiliating Genes
1 spastic paraplegia 11, autosomal recessive 34.1 SPG11 SPG21 SPG7
2 spastic paraplegia 5a, autosomal recessive 34.1 CYP7B1 PNPLA6
3 spastic paraplegia 43, autosomal recessive 34.0 CYP7B1 PNPLA6
4 spastic paraplegia 47, autosomal recessive 33.9 REEP1 WASHC5
5 spastic paraplegia 18, autosomal recessive 33.9 NIPA1 SPG21 WASHC5
6 spastic paraplegia 49, autosomal recessive 33.9 SPG11 SPG7 ZFYVE26
7 spastic paraplegia 30, autosomal recessive 33.9 KIF1A SPG21 WASHC5
8 spastic paraplegia 24, autosomal recessive 33.7 CYP7B1 SPG21 SPG7
9 spastic paraplegia 13, autosomal dominant 33.7 ATL1 HSPD1 SPAST WASHC5
10 spastic paraplegia 32, autosomal recessive 33.7 ATL1 SPG11 SPG21 SPG7
11 spastic paraplegia 44, autosomal recessive 33.7 SPG21 ZFYVE27
12 spastic paraplegia 39, autosomal recessive 33.7 PNPLA6 WASHC5 ZFYVE26
13 spastic paraplegia 8, autosomal dominant 33.6 ATL1 NIPA1 REEP1 SPG11 WASHC5
14 mast syndrome 33.6 SPG11 SPG21
15 spastic paraplegia 42, autosomal dominant 33.5 NIPA1 REEP1 SLC33A1 WASHC5
16 spastic paraplegia 61, autosomal recessive 33.5 ATL1 REEP1 RTN2 SPAST
17 spastic paraplegia 2, x-linked 33.5 ATL1 PLP1 REEP1 RTN2 ZFYVE27
18 spastic paraplegia 28, autosomal recessive 33.3 DDHD2 RTN2
19 spastic paraplegia 6, autosomal dominant 33.3 ATL1 KIF5A NIPA1 REEP1 SLC33A1 SPAST
20 masa syndrome 33.3 ATL1 NIPA1 REEP1 SPAST SPG11
21 spastic paraplegia 54, autosomal recessive 33.3 DDHD2 RTN2
22 spastic paraplegia 31, autosomal dominant 33.3 ATL1 REEP1 RTN2 SPAST ZFYVE27
23 spastic paraplegia 48, autosomal recessive 33.2 DDHD2 SPG11 SPG21 ZFYVE26
24 spastic paraplegia 56, autosomal recessive 33.2 DDHD2 RTN2
25 spastic paraplegia 7, autosomal recessive 33.1 CYP7B1 KIF1A KIF5A NIPA1 SPAST SPG11
26 spastic paraplegia 10, autosomal dominant 33.1 ATL1 KIF5A REEP1 RTN2 SPG11 ZFYVE27
27 spastic paraplegia 15, autosomal recessive 33.1 DDHD2 SPG11 SPG21 SPG7 ZFYVE26
28 spastic paraplegia 35, autosomal recessive 33.1 DDHD2 SPG11 SPG21 ZFYVE26
29 spastic paraplegia 12, autosomal dominant 33.0 ATL1 KIF5A REEP1 RTN2 SPAST ZFYVE27
30 spastic paraplegia 3, autosomal dominant 33.0 ATL1 NIPA1 REEP1 RTN2 SPAST SPG11
31 spastic paraplegia 33, autosomal dominant 32.9 REEP1 RTN2 SLC33A1 SPAST ZFYVE27
32 neuropathy, hereditary sensory, with spastic paraplegia, autosomal recessive 32.7 CYP7B1 KIF1A KIF5A NIPA1 SPAST SPG11
33 spasticity 32.6 KIF1A SPG7 WASHC5
34 spastic paraplegia 20, autosomal recessive 32.5 CYP7B1 KIF1A KIF5A NIPA1 PNPLA6 SPART
35 spastic paraplegia 4, autosomal dominant 32.3 ATL1 NIPA1 REEP1 RTN2 SLC33A1 SPAST
36 leukodystrophy, hypomyelinating, 4 31.5 HSPD1 PLP1
37 axonal neuropathy 30.4 KIF5A SPG11 ZFYVE26
38 spastic paraparesis 29.7 SPAST SPG11
39 hereditary spastic paraplegia 29.0 ATL1 CYP7B1 DDHD2 HSPD1 KIF1A KIF5A
40 spastic paraplegia 17, autosomal dominant 12.4
41 spastic paraplegia, optic atrophy, and neuropathy 12.3
42 spastic paraplegia 45, autosomal recessive 12.3
43 spastic paraplegia 46, autosomal recessive 12.3
44 spastic paraplegia 26, autosomal recessive 12.3
45 spastic paraplegia 9a, autosomal dominant 12.3
46 spastic paraplegia 57, autosomal recessive 12.3
47 spastic paraplegia 23 12.3
48 spastic paraplegia 55, autosomal recessive 12.3
49 spastic paraplegia 11 12.3
50 spastic paraplegia 72, autosomal recessive 12.2

Comorbidity relations with Paraplegia via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Hypertension, Essential Multiple Sclerosis
Neurogenic Bladder Osteoporosis
Paralytic Ileus Prostate Cancer
Protein-Energy Malnutrition Spinal Cord Disease
Vascular Myelopathy

Graphical network of the top 20 diseases related to Paraplegia:



Diseases related to Paraplegia

Symptoms & Phenotypes for Paraplegia

UMLS symptoms related to Paraplegia:


paraplegia, flaccid, monoplegia of lower limb affecting unspecified side, paraplegia, spinal, paraplegia, cerebral, monoparesis, paraplegia, ataxic, paraparesis, ophthalmoplegia, hemiplegia

MGI Mouse Phenotypes related to Paraplegia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.77 ATL1 DDHD2 HSPD1 KIF1A KIF5A PLP1
2 nervous system MP:0003631 9.4 DDHD2 HSPD1 KIF1A KIF5A PLP1 PNPLA6

Drugs & Therapeutics for Paraplegia

Drugs for Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 106)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2 diuretics Phase 4
3 Natriuretic Agents Phase 4
4 Anticonvulsants Phase 4
5 Carbonic Anhydrase Inhibitors Phase 4
6
Minocycline Approved, Investigational Phase 2, Phase 3 10118-90-8 5281021
7
Acetylcholine Approved Phase 2, Phase 3 51-84-3 187
8
Fenofibrate Approved Phase 2, Phase 3 49562-28-9 3339
9 Cortivazol Investigational Phase 3 1110-40-3
10 Anti-Bacterial Agents Phase 2, Phase 3
11 Hypolipidemic Agents Phase 2, Phase 3
12 Anti-Infective Agents Phase 2, Phase 3
13 Antimetabolites Phase 2, Phase 3
14 Anti-Inflammatory Agents Phase 3,Phase 2
15 Lipid Regulating Agents Phase 2, Phase 3
16 Fibrin Tissue Adhesive Phase 2, Phase 3,Phase 1
17 Cholinergic Agents Phase 2, Phase 3
18 Neurotransmitter Agents Phase 2, Phase 3,Phase 1
19 Botulinum Toxins Phase 2, Phase 3
20
chenodeoxycholic acid Approved Phase 2 474-25-9 10133
21
Resveratrol Approved, Experimental, Investigational Phase 2 501-36-0 445154
22
Dopamine Approved Phase 1, Phase 2 51-61-6, 62-31-7 681
23
Levodopa Approved Phase 1, Phase 2 59-92-7 6047
24
Buspirone Approved, Investigational Phase 1, Phase 2 36505-84-7 2477
25
Carbidopa Approved Phase 1, Phase 2 28860-95-9 38101 34359
26 Atorvastatin Calcium Phase 2 134523-03-8
27 Analgesics Phase 2
28 Cathartics Phase 2
29 Gastrointestinal Agents Phase 2
30 Analgesics, Non-Narcotic Phase 2
31 Peripheral Nervous System Agents Phase 2
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
33 Anticholesteremic Agents Phase 2
34 Platelet Aggregation Inhibitors Phase 2
35 Anti-Inflammatory Agents, Non-Steroidal Phase 2
36 Protective Agents Phase 2
37 Laxatives Phase 2
38 Antineoplastic Agents, Phytogenic Phase 2
39 Antioxidants Phase 2
40 Antirheumatic Agents Phase 2
41 Calcium, Dietary Phase 2
42
Serotonin Phase 1, Phase 2 50-67-9 5202
43 abobotulinumtoxinA Phase 2
44 Central Nervous System Depressants Phase 1, Phase 2
45 Serotonin Agents Phase 1, Phase 2
46 Neuromuscular Agents Phase 2
47 Tranquilizing Agents Phase 1, Phase 2
48 Hemagglutinins Phase 2
49 onabotulinumtoxinA Phase 2
50 Dopamine Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 109)

# Name Status NCT ID Phase Drugs
1 Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery Unknown status NCT01889498 Phase 4 Acetazolamide
2 Brain Function and White Matter Changes in Congenital, Acute and Chronic Spinal Cord Lesions Completed NCT01208584 Phase 4
3 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
4 Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica Unknown status NCT02151045 Phase 3
5 Retraining Walking After Spinal Cord Injury Unknown status NCT00059553 Phase 2, Phase 3
6 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Completed NCT02604186 Phase 2, Phase 3
7 Fenofibrate Treatment in SCI Recruiting NCT02455336 Phase 2, Phase 3 Fenofibrate
8 Study of the Impact of the Use of a Corset on the Respiratory Function of Patients With Spinal Cord Injury Withdrawn NCT01569360 Phase 3
9 Cethrin in Acute Cervical Spinal Cord Injury Withdrawn NCT02053883 Phase 2, Phase 3 Cethrin (BA-210);Placebo
10 Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 Unknown status NCT02314208 Phase 2 Xenbilox;Tahor
11 Spinal Cord Injury Leg Rehabilitation Completed NCT01498991 Phase 1, Phase 2
12 Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy Completed NCT02188277 Phase 2 Xeomin;Botox®
13 The Effects of Passive Gait Training in Complete Motor Spinal Cord Injury (SCI) Completed NCT01349478 Phase 1, Phase 2
14 Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury Completed NCT01484184 Phase 1, Phase 2 SPINALON (buspirone + levodopa + cardidopa)
15 A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries Completed NCT00500812 Phase 1, Phase 2 Cethrin
16 Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury Active, not recruiting NCT02326662 Phase 1, Phase 2
17 Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury Not yet recruiting NCT02574585 Phase 2
18 Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries Suspended NCT00073853 Phase 2
19 Pressure Ulcer Formation Prevention in Paraplegics Using Computer and Sensory Substitution Via the Tongue. Terminated NCT00429013 Phase 2
20 The ReWalk Exoskeletal Walking System for Persons With Paraplegia Unknown status NCT01454570 Phase 1
21 SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias Unknown status NCT00140829 Phase 1
22 Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations Unknown status NCT00136630 Phase 1
23 Improving Ambulatory Community Access After Paralysis Unknown status NCT01570816 Phase 1
24 Orthostatic Tolerance During FES (Functional Electrical Stimulation)-Walking in Paraplegia Completed NCT00108043 Phase 1
25 Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI Completed NCT01739023 Phase 1
26 Use of Interactive Gaming for Enhanced Function After Spinal Cord Injury Completed NCT01537978 Phase 1
27 Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia Completed NCT01909154 Phase 1
28 The Safety of ahSC in Chronic SCI With Rehabilitation Recruiting NCT02354625 Phase 1
29 Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and Epilepsies Terminated NCT00142363 Phase 1
30 Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia. Unknown status NCT02042508
31 Reciprocating Gait Orthoses for Paraplegia Patients Unknown status NCT02227407
32 Adjusting Wheelchair Set-Up to Minimize Shoulder Joint Forces During Propulsion Unknown status NCT00785278
33 Home/Work, Community Mobility Skills in the ReWalk Exoskeleton in Persons With SCI Unknown status NCT02118194
34 Abdominal Functional Electrical Stimulation in Tetraplegia Unknown status NCT00202631
35 Effect of Intense Multi-modal Training on Bone Health and Quality of Life in Persons With Spinal Cord Injury Unknown status NCT01386762 Early Phase 1
36 Body Composition Assessment in Spinal Cord Injury Unknown status NCT00957762
37 Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis Unknown status NCT02287363
38 Early Intervention to Reduce Bone Loss After Spinal Cord Injury Unknown status NCT02334410
39 Paraplegic Cycling: Improving Health After Spinal Cord Injury Unknown status NCT00204100
40 Safety and Tolerance of Local Heat Application in the Paralyzed Area of Patients With Complete Paraplegia Completed NCT03001531
41 Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis Completed NCT00023075
42 Effects of Exercise in People With Paraplegia Completed NCT01203150
43 Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis Completed NCT00838838 Testosterone Undeconate (Nebido-R, BAY86-5037)
44 A Study Testing Safety and Tolerance of the ReWalk Exoskeleton Suit Completed NCT00627107
45 Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO) Completed NCT01251549
46 Multimodal Exercises to Improve Leg Function After Spinal Cord Injury Completed NCT01740128
47 Exercise to Reduce Obesity in Spinal Cord Injury Completed NCT00270855
48 Finding the Optimal Voluntary Exercise Parameters for Those Living With Quadriplegia Completed NCT03146728
49 Robotically Assisted Treadmill Training in Spinal Cord Injury (SCI) Completed NCT00385918
50 Correlation Between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population Completed NCT03381716 drug

Search NIH Clinical Center for Paraplegia

Cochrane evidence based reviews: paraplegia

Genetic Tests for Paraplegia

Anatomical Context for Paraplegia

MalaCards organs/tissues related to Paraplegia:

38
Spinal Cord, Brain, Bone, Testes, Colon, Bone Marrow, Tongue

Publications for Paraplegia

Articles related to Paraplegia:

(show top 50) (show all 1332)
# Title Authors Year
1
Sacral bone cyst treatment resulting in paraplegia. ( 29351944 )
2018
2
Reply: POLR3A variants in hereditary spastic paraplegia and ataxia. ( 29236946 )
2018
3
Audio-visual distraction as an adjunct to standby anaesthesia in persons with paraplegia: a case series of five operations. ( 29423310 )
2018
4
Transient paraplegia after neurolytic splanchnic block in a patient with metastatic colon carcinoma. ( 29372026 )
2018
5
Differential changes in the spinal segmental locomotor output in Hereditary Spastic Paraplegia. ( 29353180 )
2018
6
POLR3A variants in hereditary spastic paraplegia and ataxia. ( 29228109 )
2018
7
CYP2U1 activity is altered by missense mutations in hereditary spastic paraplegia 56. ( 29034544 )
2018
8
A hereditary spastic paraplegia-associated atlastin variant exhibits defective allosteric coupling in the catalytic core. ( 29180453 )
2018
9
Clinical and neuroimaging features of autosomal recessive spastic paraplegia 35 (SPG35): case reports, new mutations, and brief literature review. ( 29423566 )
2018
10
Subtle Imaging Findings Aid the Diagnosis of Adolescent Hereditary Spastic Paraplegia and Ataxia. ( 29379980 )
2018
11
Pretreatment with diazoxide and erythropoietin: A novel strategy to prevent paraplegia after aortic surgery. ( 29409604 )
2018
12
A Rare Cause of Paraplegia: Myeloid Sarcoma. ( 29393854 )
2018
13
A case of paraplegia that developed 6A years after thoracic endovascular aortic repair for blunt traumatic aortic injury. ( 29445509 )
2018
14
Resting state fMRI studies in SPG4-linked hereditary spastic paraplegia. ( 29249364 )
2018
15
Prevalence of upper extremity pain in a population of people with paraplegia. ( 29367654 )
2018
16
Identification of IFRD1 variant in a Han Chinese family with autosomal dominant hereditary spastic paraplegia associated with peripheral neuropathy and ataxia. ( 29362493 )
2018
17
Voluntary ambulation using voluntary upper limb muscle activity and Hybrid Assistive LimbAr (HALAr) in a patient with complete paraplegia due to chronic spinal cord injury: A case report. ( 29351051 )
2018
18
Physical Training and Upper Limb Strength of people with paraplegia: A Systematic Review. ( 29364066 )
2018
19
Effect of exoskeletal joint constraint and passive resistance on metabolic energy expenditure: Implications for walking in paraplegia. ( 28817701 )
2017
20
Posterior-only vertebral column resection for revision surgery in post-laminectomy rotokyphoscoliosis associated with late-onset paraplegia: A case report and literature review. ( 28072705 )
2017
21
PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia. ( 28295203 )
2017
22
A new phenotype associated with homozygous GRN mutations: complicated spastic paraplegia. ( 28000352 )
2017
23
A Case of Acute Paraplegia Due to Aortic Dissection in Marfan Syndrome. ( 28479826 )
2017
24
Hereditary spastic paraplegia: More than an upper motor neuron disease. ( 28449883 )
2017
25
Defects in ER-endosome contacts impact lysosome function in hereditary spastic paraplegia. ( 28389476 )
2017
26
Epidural Haematoma Causing Paraplegia in a Patient with Ankylosing Spondylitis: A Case Report. ( 28824860 )
2017
27
SPG20 mutation in three siblings with familial hereditary spastic paraplegia. ( 28679690 )
2017
28
Severe 5,10-methylenetetrahydrofolate reductase deficiency: a rare, treatable cause of complicated hereditary spastic paraplegia. ( 29284203 )
2017
29
Segmentation of gait sequences using inertial sensor data in hereditary spastic paraplegia. ( 29060107 )
2017
30
Complicated hereditary spastic paraplegia due to ATP13A2 mutations: what's in a name? ( 29112699 )
2017
31
Patterns and modulations of Pendular nystagmus in a family with hereditary spastic paraplegia. ( 29246608 )
2017
32
Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis. ( 28716533 )
2017
33
Cannabinoids for spasticity due to multiple sclerosis or paraplegia: A systematic review and meta-analysis of randomized clinical trials. ( 28917371 )
2017
34
Clinical and genetic study of hereditary spastic paraplegia in Canada. ( 27957547 )
2017
35
Novel mutations c. [453dupA] + [663G > A] of the SPG11 gene associated with hereditary spastic paraplegia with a thin corpus callosum. ( 28681766 )
2017
36
Thyrotoxic Neuropathy: A rare cause of acute flaccid paraplegia. ( 29372090 )
2017
37
Author response: Clinical Reasoning: A young woman with respiratory failure, hearing loss, and paraplegia. ( 28847834 )
2017
38
Febrile ataxia and myokymia broaden the SPG26 hereditary spastic paraplegia phenotype. ( 28626794 )
2017
39
Hereditary spastic paraplegia type 35 caused by a novel FA2H mutation. ( 29376581 )
2017
40
Effects of resistance-guided high intensity interval functional electrical stimulation cycling on an individual with paraplegia: A case report. ( 28868988 )
2017
41
Active lower limb orthosis with one degree of freedom for people with paraplegia. ( 28813828 )
2017
42
Reply: Complicated hereditary spastic paraplegia due to ATP13A2 mutations: what's in a name? ( 29112700 )
2017
43
Energy balance components in persons with paraplegia: daily variation and appropriate measurement duration. ( 28950900 )
2017
44
Paraplegia in Subarachnoid Hemorrhage Complicated With Coarctation of Aorta: An Unusual Complication. ( 28816884 )
2017
45
Correction: Targeted high throughput sequencing in hereditary ataxia and spastic paraplegia. ( 29023604 )
2017
46
Hypertension, acute stent thrombosis and paraplegia 6 months after TEVAR for blunt thoracic aortic injury in a 22 year old patient. ( 28893706 )
2017
47
Study on the Effectiveness of Virtual Reality Game-Based Training on Balance and Functional Performance in Individuals with Paraplegia. ( 29339902 )
2017
48
Author response: Clinical Reasoning: A young woman with respiratory failure, hearing loss, and paraplegia. ( 28847836 )
2017
49
Paraplegia After Off-Pump Coronary Artery By-Pass Grafting. ( 29373889 )
2017
50
Progressive hereditary spastic paraplegia caused by a homozygous KY mutation. ( 28488683 )
2017

Variations for Paraplegia

Copy number variations for Paraplegia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 170541 3 155544315 155572167 Copy number SLC33A1 Paraplegias

Expression for Paraplegia

Search GEO for disease gene expression data for Paraplegia.

Pathways for Paraplegia

Pathways related to Paraplegia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 KIF5A SPART SPG21 WASHC5 ZFYVE27

GO Terms for Paraplegia

Cellular components related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.81 ATL1 CYP7B1 PNPLA6 REEP1 RTN2 SLC33A1
2 axon GO:0030424 9.62 ATL1 KIF1A SPG11 ZFYVE27
3 midbody GO:0030496 9.58 SPART SPAST ZFYVE26
4 endoplasmic reticulum membrane GO:0005789 9.56 ATL1 CYP7B1 PNPLA6 REEP1 RTN2 SLC33A1
5 axon cytoplasm GO:1904115 9.43 KIF1A SPAST SPG7
6 endoplasmic reticulum tubular network GO:0071782 8.8 ATL1 REEP1 ZFYVE27
7 membrane GO:0016020 10.24 ATL1 CYP7B1 DDHD2 HSPD1 KIF5A NIPA1

Biological processes related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid particle organization GO:0034389 8.96 DDHD2 SPART
2 anterograde axonal transport GO:0008089 8.8 KIF1A SPAST SPG7

Molecular functions related to Paraplegia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 8.92 KIF1A KIF5A REEP1 SPAST

Sources for Paraplegia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....